Clinical Trial Update: Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating long-acting maintenance therapy with albuvirtide and 3BNC117 in virologically suppressed HIV-1-infected individuals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• 3BNC117
• albuvirtide (albuvirtide)

Snippet

Sponsor: Frontier Biotechnologies Inc. | Conditions: HIV-1-infection | Phase 2 | Status: UNKNOWN